Here's How Much Eli Lilly's Weight-Loss Drugs Are Worth to Investors

Eli Lilly's weight-loss and diabetes drugs Mounjaro and Zepbound generated $12.8 billion in Q1 2026 revenue, representing nearly two-thirds of the company's total revenue. Mounjaro showed accelerating growth at 125% year-over-year, while the company raised its 2026 guidance to $82-85 billion. The FDA approval of Foundayo, a once-daily GLP-1 pill, expands the franchise's market reach. However, the company's valuation heavily depends on this single drug family, presenting both significant opportunity and concentration risk.

07/13/2026, 4:23 AM • The Motley Fool

3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026

The article recommends three high-yield dividend stocks for the second half of 2026: Novo Nordisk (3.5% yield) is positioned to regain market share in GLP-1 drugs with its superior pill formulation despite pricing pressures; Realty Income (5% yield) offers stable, conservative dividend growth through its diversified net lease REIT portfolio; and Enterprise Products Partners (5.9% yield) provides reliable energy infrastructure income through a toll-taker model insulated from oil price volatility.

07/11/2026, 9:15 AM • The Motley Fool

History Says Doing This 1 Thing Will Score You an Investing Win -- Even After a Market Crash.

Despite recent market gains driven by AI stocks, valuations are at historically expensive levels similar to the dot-com bubble. The article recommends a simple strategy: invest in quality stocks and hold them long-term. History shows the S&P 500 has always recovered after crashes, making buy-and-hold the key to investing success.

07/11/2026, 4:02 AM • The Motley Fool

Novo Nordisk’s $50 Price Frames a Value Versus Value Trap Debate

Novo Nordisk trades near $50, down 75% from its June 2024 peak of $142.44, caught between a turnaround narrative and structural decline thesis. The stock has recovered from $35 lows on the back of a blockbuster oral Wegovy pill launch and Q1 earnings beat, but faces persistent headwinds from Eli Lilly's competitive dominance in GLP-1 drugs, pipeline setbacks with CagriSema, US pricing pressure, and patent erosion. At 11.8x forward earnings with a 3.6% dividend yield, the market is divided on whether the stock represents genuine value or a value trap.

07/10/2026, 2:10 PM • Investing

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?

Vanguard Health Care ETF (VHT) offers broad diversification across 429 healthcare holdings with a low 0.09% expense ratio, while VanEck Pharmaceutical ETF (PPH) provides concentrated exposure to 26 drugmakers with higher returns but greater risk. VHT is more cost-effective and diversified, while PPH has delivered superior 5-year returns and higher dividend yield despite concentration risk and a higher 0.36% expense ratio.

07/09/2026, 8:15 AM • The Motley Fool

Invesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026?

The article compares two healthcare-focused ETFs: Invesco Pharmaceuticals ETF (PJP) and First Trust NYSE Arca Biotechnology Index Fund (FBT). PJP focuses on established pharmaceutical companies with lower volatility and dividend income, while FBT targets high-growth biotech stocks with greater exposure to small and mid-cap companies. Despite FBT's stronger 10-year performance, PJP is recommended as the better buy due to its superior 5-year returns, lower volatility, dividend yield, and more stable risk profile.

07/08/2026, 6:04 PM • The Motley Fool

Is It Too Late to Buy Eli Lilly?

Eli Lilly stock has surged 400% over five years, driven by dominance in the GLP-1 weight loss drug market with products like Mounjaro and Zepbound generating over $12 billion in recent quarterly sales. Despite the stock's significant gains and current $1,200+ price, analysts suggest it remains reasonably valued with strong growth prospects from its oral drug Foundayo and promising pipeline candidate retatrutide, making it still worth considering for investors.

07/08/2026, 2:10 PM • The Motley Fool

Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026

Eli Lilly's stock is predicted to reach $1,400 by end of 2026 (15% gain from July levels), driven by expanded drug access rather than efficacy. The company's new oral obesity drug Foundayo, combined with $27 billion in manufacturing expansion, direct pharmacy distribution, and Medicare pricing deals, positions it to reach patients that injectable competitors cannot. However, competition from Novo Nordisk, premium valuation, and execution risks remain concerns.

07/08/2026, 8:30 AM • The Motley Fool

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners?

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with 25 concentrated holdings and State Street SPDR S&P Pharmaceuticals ETF (XPH) with 65 diversified holdings. Both charge identical 0.35% expense ratios and offer 0.50% dividend yields, but XPH delivered significantly higher 1-year returns (64.30% vs 33.30%) and lower volatility, making it potentially more suitable for beginners seeking diversification.

07/08/2026, 7:28 AM • The Motley Fool

Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom

While Eli Lilly and Novo Nordisk are leaders in the GLP-1 market, Becton, Dickinson and Abbott Laboratories offer better indirect exposure to the GLP-1 boom. Becton, Dickinson supplies prefillable syringes with soaring demand and is a Dividend King, while Abbott's continuous glucose monitoring devices see increased adoption alongside GLP-1 medicines.

07/07/2026, 5:30 PM • The Motley Fool

Hims & Hers Pullback Could Create a Better Entry Into GLP-1 Demand

Hims & Hers (HIMS) has surged 45% in the past month and 160% year-to-date, but technical indicators suggest a correction is due. However, a major catalyst looms: employers are planning to drop GLP-1 drug coverage in 2027, which should drive patients to direct-to-consumer telehealth providers like Hims & Hers. The stock's RSI is overbought at 70.86, and Wall Street remains bearish with only 4 of 16 analysts rating it a Buy, suggesting a pullback could present a better entry point for long-term investors.

07/07/2026, 11:37 AM • Investing

Is It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years.

Eli Lilly is positioned to benefit from the booming obesity drug market, projected to grow from $15 billion in 2024 to $150 billion by 2035. With new products like the pill-form Foundayo and next-generation Retatrutide in development, analysts expect 15% annual earnings growth over the next decade. At current valuations, a $1,000 investment could potentially grow to approximately $2,580 in 10 years, suggesting the stock still offers attractive long-term returns despite its 160% surge over the past three years.

07/07/2026, 8:10 AM • The Motley Fool

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Eli Lilly and Teva Pharmaceutical represent two different pharmaceutical strategies: Eli Lilly dominates the high-growth GLP-1 market with blockbuster drugs like Mounjaro and Zepbound, posting 44% revenue growth and trading at a 33x forward P/E. Teva operates in generics and biosimilars with lower valuations (16.4x forward P/E) but faces declining sales projections for 2026 and significant debt challenges. The article recommends Eli Lilly as the better buy despite premium valuation due to its continued GLP-1 growth momentum.

07/06/2026, 1:09 PM • The Motley Fool

Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?

Viking Therapeutics' lead drug candidate VK2735, a dual GLP-1/GIP agonist, shows promise in the competitive weight-loss market with potential for rapid weight loss via injectable form followed by oral maintenance. However, the company faces significant risks including safety concerns from phase 2 trials, long development timelines (phase 3 results not expected until 2027-2028), and likely acquisition by a larger pharmaceutical company if successful.

07/06/2026, 7:15 AM • The Motley Fool

Grey Matters Takes Delivery of the First Brain Dedicated PET Scanning System for its Flagship NovaScan Neuroimaging Clinic in Florida

Grey Matters Health Inc. has received its first brain-dedicated PET scanning system (CareMiBrain) for its flagship NovaScan Neuroimaging Clinic in Davie, Florida, positioning itself as the first U.S. clinic to offer brain-only PET scans for early Alzheimer's detection. The clinic will capitalize on the emerging billion-dollar market created by FDA-approved monoclonal antibody treatments (Leqembi and Kisunla) that require beta-amyloid brain imaging for patient authorization and monitoring.

07/06/2026, 7:00 AM • GlobeNewswire